ExomeDNAExomeDNA
Read your report

LDL Cholesterol and Your Genetics

LDL cholesterol (low-density lipoprotein) is the lipoprotein fraction most consistently linked to cardiovascular disease — and a substantial share of where your levels naturally settle is set by genes, not just diet. Twin and family studies estimate that inherited factors account for roughly 40 to 60 percent of LDL variability between individuals.[1] Genome-wide studies have mapped dozens of genetic loci linked to LDL levels, implicating genes including ABCA1, ABCG8, and A1CF, among many others.[2, 3] Below: how these variants shape LDL, the genes most consistently implicated, and what the evidence says about lifestyle interaction.

What is LDL cholesterol?

LDL (low-density lipoprotein) transports cholesterol from the liver to tissues throughout the body. When it accumulates in artery walls, it drives the inflammatory plaque buildup underlying most heart attacks and strokes. Most clinical guidelines recommend LDL-C levels below 100 mg/dL for adults without established cardiovascular disease.

Each LDL particle is assembled in the liver and carries a core of cholesterol esters stabilized by a single molecule of apolipoprotein B-100. This protein binds to LDL receptors on liver cells, initiating particle clearance from the bloodstream. Genetic variants that alter VLDL and LDL production rates, reduce receptor expression, or change the efficiency of LDL clearance all shift the baseline LDL level an individual settles into, often independently of diet.

The genetics behind LDL cholesterol

LDL cholesterol is one of the most heritable common biomarkers. Large-scale genetic studies conducted over the past two decades have identified multiple genomic regions influencing LDL levels, with effects distributed across many genes rather than concentrated in a single dominant variant.[2, 3, 4]

Several gene families contribute the majority of the identified genetic signal:

ABCA1 and the ABC transporter family: ABCA1 (ATP-binding cassette transporter A1) encodes a protein that transports cholesterol out of cells and into nascent HDL particles — the first step in reverse cholesterol transport. This efflux process affects how cholesterol is distributed across lipoprotein fractions, with downstream effects on LDL levels. ABCA6 and ABCA8 belong to the same transporter family and have each been associated with lipid traits in large genetic studies.[5] ABCB1, ABCB4, and ABCB11 are additional ABC-family members identified in LDL-linked genomic regions. ABCG5 and ABCG8 function as a pair in the intestinal wall, limiting how much dietary cholesterol enters the bloodstream. Variants in ABCG8 that impair this absorption checkpoint raise the cholesterol load delivered to the liver, pushing LDL higher independently of total calorie intake.

Apolipoprotein B RNA editing: A1CF (APOBEC-1 complementation factor) is part of the enzyme complex that edits apolipoprotein B messenger RNA — a post-transcriptional step determining whether the intestinal form (apoB-48) or the liver form (apoB-100) of apolipoprotein B is produced. The liver form, apoB-100, is the structural protein present on every LDL and VLDL particle; variants in A1CF that shift this editing balance affect LDL particle assembly and composition.

95 genetic loci associated with blood lipid levels — including 59 newly discovered regions — were identified in a genome-wide analysis of more than 100,000 individuals. The breadth of discovery confirmed that LDL's genetic architecture spans dozens of biological pathways, not a handful of core genes.[5]

What the research says

Research base: Robust. The genetic epidemiology of LDL cholesterol is one of the best-characterized areas in human genomics. Studies beginning in 2008 identified the first reproducible genome-wide associations with LDL levels, documenting novel loci beyond the pathways known from familial hypercholesterolemia genetics.[1, 2, 3] Subsequent larger studies confirmed the polygenic architecture — many common variants with moderate individual effects — and demonstrated cross-population replication for key loci.[6, 7]

Studies across multiple independent cohorts consistently show that at least 30 genetic loci contribute to the polygenic architecture of LDL in general populations, with additional loci identified as sample sizes grow.[4] Mendelian randomization analyses — which use genetic variants as natural experiments to test causal relationships — have provided strong evidence that lower LDL levels cause fewer cardiovascular events, giving clinical weight to the genetic signal.

Common variants across 30 or more genetic loci contribute to polygenic dyslipidemia in the general population, demonstrating that most LDL variation outside familial conditions reflects a distributed architecture of many moderate-effect variants — a finding that shapes how LDL genetic risk is calculated and communicated.[4]

The evidence base for LDL genetics has been replicated across European, East Asian, South Asian, and African American populations, with consistent directional effects at major loci and some variation in allele frequencies and effect magnitudes.[5, 6] ExomeDNA's methodology page provides additional context on how genetic signals across loci are integrated into an ancestry-aware composite score.

How LDL cholesterol affects you

People whose inherited variants favor higher LDL production or reduced clearance tend to run higher baseline LDL from early adulthood, independent of diet. This genetic baseline has several practical implications:

Cumulative exposure matters. LDL acts on artery walls over decades. Two people with identical LDL levels at age 40 can have very different arterial plaque burdens depending on their trajectory over the preceding 20 years — meaning genetic tendencies toward higher LDL from earlier in life compound over time.

Dietary response is real but variable. Saturated fat reduction, soluble fiber, and plant sterols reliably lower LDL across all genetic backgrounds, but the magnitude of reduction differs between individuals. People carrying variants affecting ABCG8 (intestinal absorption) may see a stronger response to dietary cholesterol reduction than the population average, while those with ABCA1-related variants may respond differently through cholesterol efflux pathways.

Genetic LDL differs from secondary LDL elevation. High LDL from genetic causes behaves differently from LDL elevated by hypothyroidism, metabolic syndrome, or certain medications. Understanding the most likely source can guide the most targeted intervention.

The LDL number alone has limits. People with genetically lower LDL but other unfavorable cardiovascular markers — elevated triglycerides, insulin resistance, strong family history — may still carry meaningful cardiovascular risk. Genetic LDL is one data point in a broader picture.

Working with your result

What research supports for managing LDL:

  1. Reduce saturated fat intake — the most consistently effective dietary intervention, lowering LDL across all genetic backgrounds. Largest sources in most diets: full-fat dairy, fatty cuts of meat, tropical oils, and ultra-processed snack foods.
  2. Increase soluble fiber — oats, legumes, barley, and psyllium husk bind bile acids in the gut, prompting the liver to draw more cholesterol from the blood. This effect operates independently of saturated fat intake.
  3. Add plant sterols and stanols (2 grams per day in fortified foods) — these molecules compete with cholesterol at the ABCG5/ABCG8 absorption pathway, making them particularly relevant for people with variants affecting intestinal cholesterol uptake.
  4. Exercise regularly with aerobic components — consistent aerobic training improves LDL particle size distribution, shifting toward larger, less atherogenic particles, even when total LDL-C changes modestly.
  5. Manage body weight — excess adipose tissue increases VLDL production, which converts to LDL in circulation. Weight reduction in people with excess body weight reliably lowers LDL-C.
  6. Monitor with regular lipid panels — repeated fasted measurements over time show actual LDL trajectory, which is more informative than a single reading, especially when making lifestyle changes.
  7. Discuss pharmacological options with a clinician if lipid panel results remain above targets after sustained lifestyle effort — statins, ezetimibe, and PCSK9 inhibitors each target distinct pathways in LDL metabolism and may address different genetic mechanisms depending on the underlying biology.

LDL cholesterol shares genetic architecture with several related traits:

  • HDL Cholesterol — the reverse cholesterol transport partner; genes like ABCA1 influence both HDL and LDL levels through cholesterol redistribution pathways.
  • Triglycerides — VLDL overproduction elevates both triglycerides and LDL; the traits share genetic contributors in several pathways.
  • Apolipoprotein B — a direct count of LDL and VLDL particles, often considered a more complete predictor of cardiovascular risk than LDL-C alone; the two traits are biologically linked through apolipoprotein B-100.
  • Cardiovascular Disease Risk — LDL is a primary input to polygenic cardiovascular risk scoring; many LDL loci are also cardiovascular disease risk loci.
  • Plant Sterol Absorption — particularly relevant for people with ABCG8 variants affecting intestinal sterol transport.

Frequently asked questions

How much of my LDL cholesterol level is genetic? A meaningful fraction. Twin and family studies consistently estimate that 40 to 60 percent of LDL variability between individuals is inherited, with the remainder driven by diet, body weight, physical activity, metabolic health, and medications.[1] Lifestyle matters alongside genetics — neither tells the full story on its own.

What genes most strongly influence LDL cholesterol? Multiple genes contribute across different biological steps. ABCG5 and ABCG8 influence how much cholesterol is absorbed from food. ABCA1 governs how cells offload cholesterol into the HDL pathway. A1CF shapes the form of apolipoprotein B produced in the intestine, affecting LDL particle composition. Dozens of additional loci across lipid synthesis, transport, and receptor clearance pathways each contribute smaller effects.[2, 3, 4]

Can I lower my LDL through diet even if genetics pushes it higher? Yes, though the degree varies. Reducing saturated fat, increasing soluble fiber, adding plant sterols, and managing body weight all consistently lower LDL. People with strong genetic tendencies toward higher LDL often need combined lifestyle and pharmacological approaches to reach clinical targets — a conversation best had with a clinician who can review your full lipid profile and cardiovascular risk picture.

Is genetically high LDL the same as familial hypercholesterolemia? No. Familial hypercholesterolemia involves rare, high-impact variants in specific genes that produce dramatically elevated LDL from early childhood, typically requiring treatment from a young age. What most population-level LDL genetic profiles measure is the contribution of many common variants across dozens of loci — a polygenic picture different from familial hypercholesterolemia in both mechanism and magnitude.

Does a high LDL genetic score mean I will have a heart attack? No. Research consistently shows that LDL is one of several factors contributing to cardiovascular outcomes. A genetic tendency toward higher LDL is a risk factor, not a predetermined outcome. Overall cardiovascular risk depends on blood pressure, metabolic health, smoking status, family history, inflammatory markers, and many other factors. A clinician can help put the genetic information in that fuller context.

References

  1. Wallace C et al. (2008). Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet, 82(1):139–49. PMID: 18179892.
  2. Willer CJ et al. (2008). Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet, 40(2):161–9. PMID: 18193043.
  3. Kathiresan S et al. (2008). Six new loci associated with blood LDL cholesterol, HDL cholesterol or triglycerides in humans. Nat Genet, 40(2):189–97. PMID: 18193044.
  4. Kathiresan S et al. (2009). Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet, 41(1):56–65. PMID: 19060906.
  5. Teslovich TM et al. (2010). Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 466(7307):707–13. PMID: 20686565.
  6. Waterworth DM et al. (2010). Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol, 30(11):2264–76. PMID: 20864672.
  7. Sabatti C et al. (2009). Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet, 41(1):35–46. PMID: 19060910.

Data sources:

  • GWAS Catalog (NHGRI-EBI, accessed 2026-05-26)
  • Open Targets Platform (CC0 1.0, accessed 2026-05-26)
  • ClinVar (NCBI, accessed 2026-05-26) — entries at ≥2-star review status
  • ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-26)

Explore ExomeDNA's methodology page for more on how genetic associations are assessed and scored.

Related traits

Browse all traits →